成纤维细胞激活蛋白抑制剂PET/CT:一种有前景的分子成像工具
本文综述了放射性标记FAP抑制剂(FAPI)PET/CT的临床前与临床数据,涵盖其病理生理基础、放射性药物特性及在肿瘤与非肿瘤病变中的应用。早期证据显示FAPI PET/CT在肿瘤成像中具有前景,部分癌症优于18F-FDG PET/CT,并具诊疗一体化潜力,但现有证据有限,需进一步研究。
要点
- FAPI PET/CT在多种癌症成像中展现潜力,部分优于18F-FDG PET/CT。
- FAPI PET/CT具诊疗一体化潜力,值得关注。
- 现有证据有限,需更多研究验证其临床价值。
核心结论
- FAPI PET/CT有潜力成为未来强大的分子成像工具,但现有证据有限,需进一步研究和试验。
研究设计与样本
- 本文为综合性综述,汇总了FAPI PET/CT的临床前与临床数据,讨论其病理生理基础、放射性药物特性及在肿瘤与非肿瘤病变中的研究。
主要发现
- 基于早期科学证据,FAPI PET/CT在肿瘤学中看似有前景,可用于多种癌症成像,部分优于18F-FDG PET/CT。
- FAPI PET/CT的诊疗一体化潜力值得特别关注。
临床怎么用
- FAPI PET/CT可作为肿瘤分子成像的潜在工具,尤其在部分癌症中可能优于18F-FDG PET/CT,并可探索诊疗一体化应用。
局限性
- 现有证据有限,需进一步研究和试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein (FAP) is a cell membrane-bound serine peptidase, overexpressed in cancer-associated fibroblasts and activated fibroblasts at wound healing/inflammatory sites. Recently, molecular PET/CT imaging with radiolabeled FAP inhibitor (FAPI) has been evaluated in different diseases. We aimed to assess its potential role based on the available literature. PATIENTS AND METHODS: We conducted a comprehensive review of the available preclinical and clinical data on FAPI PET/CT in an attempt to summarize its current status and potential future role. Based on that, we have discussed the pathophysiology behind FAP-based imaging, followed by a discussion of FAPI radiopharmaceuticals including their synthesis, biodistribution, and dosimetry. Next, we have discussed studies evaluating FAPI PET/CT in different oncological and nononcological pathologies. The potential of FAPI PET/CT in theranostics has also been addressed. RESULTS: Based on the early scientific evidence available, including preclinical and clinical studies, FAPI PET/CT seems to be a promising molecular imaging tool, especially in oncology. It can be used for imaging different types of cancers and outperforms 18F-FDG PET/CT in some of these. Its potential as a theranostic tool warrants special attention. CONCLUSIONS: Fibroblast activation protein inhibitor PET/CT has the potential to emerge as a powerful molecular imaging tool in the future. However, as of yet, the available evidence is limited, warranting further research and trials in this field.
引用
- Sharma P, Singh SS, Gayana S, et al. Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool. Clin Nucl Med. 2021. PMID: 33351507. doi:10.1097/RLU.0000000000003489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。